David Strayer

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search
Source:GlobeNewswire

David R. Strayer, M.D. is the Chief Scientific & Medical Officer of Hemispherx Biopharma, the makers of Ampligen. Formerly a Professor of Medicine at the Medical College of Pennsylvania and Hahnemann University from 1987 to 1998. Board Certified in Medical Oncology and Internal Medicine with research interests in the fields of cancer and immune system disorders. Principal investigator in studies funded by the Leukemia Society of America, the American Cancer Society, and the National Institutes of Health.[1]

Notable Studies[edit | edit source]

References[edit | edit source]

  1. Hemispherx Biopharma Management 
  2. Ablashi, DV; Berneman, ZN; Williams, M; Strayer, D; Kramarsky, B; Suhadolnik, RJ; Reichenbach, N; Hiltzges, P; Komaroff, AL (1994), "Ampligen inhibits human herpesvirus-6 in vitro", In Vivo, 8 (4): 587-91, PMID 7893986 
  3. Strayer, DR; Carter, WA; Brodsky, I; Cheney, P; Peterson, D; Salvato, P; Thompson, C; Loveless, M; Shapiro, DE; Elsasser, W (1994), "A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome", Clinical Infectious Diseases, 18 (Suppl 1): S88-95, PMID 8148460 
  4. Strayer, DR; Carter, W; Strauss, KI; Brodsky, I; Suhadolnik, R; Ablashi, D; Henry, B; Mitchell, WM; Bastien, S; Peterson, D (1995), "Long Term Improvements in Patients with Chronic Fatigue Syndrome Treated with Ampligen", Journal of Chronic Fatigue Syndrome, 1 (1): 35-53, doi:10.1300/J092v01n01_04 
  5. VanNess, J Mark; Snell, Christopher R; Fredrickson, Dean M.; Strayer, David R.; Stevens, Staci R (2001), "Assessment of Functional Impairment by Cardiopulmonary Exercise Testing in Patients with Chronic Fatigue Syndrome", Journal of Chronic Fatigue Syndrome, 8 (3-4): 103-109, doi:10.1300/J092v08n03_09 
  6. Snell, Christopher R; Van Ness, J Mark; Strayer, David R; Stevens, Staci R (2005), "Exercise capacity and immune function in male and female patients with Chronic Fatigue Syndrome (CFS)" (PDF), In Vivo, 19: 387-390, PMID 15796202 
  7. Takeshi Ichinohe, Shin-ichi Tamura, Akira Kawaguchi, Ai Ninomiya, Masaki Imai, Shigeyuki Itamura, Takato Odagiri, Masato Tashiro, Hidehiro Takahashi, Hirofumi Sawa, William M. Mitchell, David R. Strayer, William A. Carter, Joe Chiba, Takeshi Kurata, Tetsutaro Sata and Hideki Hasegawa. The Journal of Infectious Diseases, Vol. 196, No. 9 (Nov. 1, 2007), pp. 1313-1320. Url: http://www.jstor.org/stable/30086851
  8. Strayer, DR; Carter, WA; Stouch, BC; Stevens, SR; Bateman, L; Cimoch, PJ; Lapp, CW; Peterson, DL; Chronic Fatigue Syndrome AMP-516 Study Group; Mitchell, WM (2012), "A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.", PLoS One, 7 (3): e31334, doi:10.1371/journal.pone.0031334, PMID 22431963 
  9. Strayer, David; Scott, Victoria; Carter, William (2015-07-29), "Low NK Cell Activity in Chronic Fatigue Syndrome (CFS) and Relationship to Symptom Severity", Journal of Clinical & Cellular Immunology: 1–9, doi:10.4172/2155-9899.1000348, ISSN 2155-9899 
  10. Strayer, David R; Stouch, Bruce C; Stevens, Staci R.; Bateman, Lucinda; Lapp, Charles W; Peterson, Daniel L; Carter, William A; Mitchell, William M (8 August 2015), "Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME): Characteristics of Responders to Rintatolimod" (PDF), Journal of Drug Research and Development, 1 (1), doi:10.16966/2470-1009.103 


The information provided at this site is not intended to diagnose or treat any illness.

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history